Angelini Pharma said on Thursday that it would acquire U.S. rare-disease drug maker Catalyst Pharmaceuticals (CPRX.O), opens new tab in a $4.1 billion deal, marking the Italian drugmaker's entry into the U.S. pharmaceutical market. The Italian group specialises in drugs treating brain diseases and its CEO Sergio Marullo di Condojanni said the deal would establish it as a "relevant global player in neurological rare diseases," expanding Angelini's scale and capabilities.
It is the second major U.S. acquisition announced by an Italian pharmaceutical company in two weeks, following Chiesi’s $1.9 billion buyout of KalVista Pharmaceuticals (KALV.O), as Italian drugmakers seek to become international players in their field.
